REGN Share Price

Open 375.10 Change Price %
High 377.89 1 Day -2.89 -0.78
Low 369.05 1 Week -17.29 -4.47
Close 369.82 1 Month 28.43 8.33
Volume 655000 1 Year -188.84 -33.80
52 Week High 563.79
52 Week Low 325.35
REGN Important Levels
Resistance 2 378.01
Resistance 1 374.64
Pivot 372.25
Support 1 365.00
Support 2 361.63
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SIRI 4.33 0.70%
SUSQ 14.20 -0.77%
AAPL 109.10 -0.73%
AAPL 109.10 -0.73%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LLEN 0.03 50.00%
LOCM 0.09 50.00%
RITT 0.09 50.00%
MEMP 0.64 33.33%
SKBI 0.19 26.67%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CLNT 0.88 23.94%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
LIWA 0.01 -50.00%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)

REGN Technical Analysis 3
As on 5th Dec 2016 REGN Share Price closed @ 369.82 and we RECOMMEND Sell for LONG-TERM with Stoploss of 396.07 & Sell for SHORT-TERM with Stoploss of 387.20 we also expect STOCK to react on Following IMPORTANT LEVELS.
REGN Target for December
1st Target up-side 448.79
2nd Target up-side 497.53
3rd Target up-side 546.28
1st Target down-side 309.69
2nd Target down-side 260.95
3rd Target down-side 212.2
REGN Other Details
Segment EQ
Market Capital 13942355968.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.regeneron.com
REGN Address
REGN
777 Old Saw Mill River Road
Tarrytown, NY 10591
United States
Phone: 914-347-7000
Interactive Technical Analysis Chart Regeneron Pharmaceuticals, Inc. ( REGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Regeneron Pharmaceuticals, Inc.
REGN Business Profile
Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.